Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Nisoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.94 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.91 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | HRH1 | P35367 | 2/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | DRD3 | P35462 | 2/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | HTR2B | P41595 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoxetine SCHEMBL3892886 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL124289 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL29401038 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL30026153 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL3897550 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL467262 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL29440249 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Nisoxetine SCHEMBL4083146 | 0.90 | SLC6A4 (0.86) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| [3H]Nisoxetine SCHEMBL29463855 | 0.87 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 | |
| Atomoxetine SCHEMBL1648558 | 0.85 | SLC6A4 (0.94) | SLC6A4SLC6A2CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024677-A1 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS | TFAM, TXNRD2, CPT1B | SLC6A2 270/4885SLC6A3 563/4885CHRM1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.